[Interpretation of the WHO guidance for best practices for clinical trials and its implications for China].

Authors

Y M Huang, R Z Wang, W Zhang, M Xu

Published in

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]. Volume 60. Issue 10. Pages 1700-1703. Oct 06, 2026.

Abstract

Public health emergencies are occurring with increasing frequency, yet persistent shortcomings in the quality and efficiency of clinical research remain unresolved. Building a clinical trial system that is scientifically rigorous, efficient, safe, reliable, and ethically sound is a common task for all countries. In response, the World Health Organization (WHO) issued the Guidance for Best Practices for Clinical Trials to improve the efficiency of clinical research, reduce avoidable waste, and support the sustained conduct of high-quality trials. This article reviews the core content of the Guidance in the context of China's current clinical trial system, identifies priorities for its application in China, and explores China's potential role in strengthening the global clinical trial ecosystem.

PMID:
42893920
Bibliographic data and abstract were imported from PubMed on 19 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.